Sartorius Stedim Biotech (56S1) Stock Statistics & Valuation Metrics

Sartorius Stedim Biotech has a market cap or net worth of EUR 22.07B. The enterprise value is EUR 22.86B.

Market Cap

EUR 22.07B

Enterprise Value

EUR 22.86B

Sartorius Stedim Biotech has 97,330,410 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

97,330,410

Owned by Insiders

―

Owned by Institutions

6.93%

Sartorius Stedim Biotech’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.44%.

Return on Equity (ROE)

0.06

Return on Assets (ROA)

0.03

Return on Invested Capital (ROIC)

5.44%

Return on Capital Employed (ROCE)

0.08

Revenue Per Employee

283.08K

Profits Per Employee

25.34K

Employee Count

10,483

Asset Turnover

0.37

Inventory Turnover

2.35

The current PE Ratio of Sartorius Stedim Biotech is 66.83. Sartorius Stedim Biotech’s PEG ratio is 2.82.

PE Ratio

66.83

PS Ratio

7.09

PB Ratio

4.96

Price to FCF

80.58

Price to Operating Cash Flow

35.11

PEG Ratio

2.82

In the last 12 months, Sartorius Stedim Biotech had revenue of 2.97B and earned 265.60M in profits. Earnings per share was 2.73.

Revenue

2.97B

Gross Profit

1.35B

Operating Income

549.00M

Pretax Income

373.20M

Net Income

265.60M

EBITDA

867.10M

Earnings Per Share (EPS)

2.73

In the last 12 months, operating cash flow was 618.50M and capital expenditures -349.00M, giving a free cash flow of 269.50M billion.

Operating Cash Flow

618.50M

Free Cash Flow

269.50M

Free Cash Flow per Share

2.77

Sartorius Stedim Biotech pays an annual dividend of ―, resulting in a dividend yield of 0.31%

Dividend Per Share

―

Dividend Yield

0.31%

Payout Ratio

N/A

Free Cash Flow Yield

1.24%

Earnings Yield

1.49%

Beta

1.10

52-Week Price Change

15.38%

50-Day Moving Average

210.87

200-Day Moving Average

183.29

Relative Strength Index (RSI)

54.36

Average Volume (3m)

63

Sartorius Stedim Biotech upcoming earnings date is Feb 23, 2027, Before Open (Not Confirmed).

Last Earnings Date

Oct 22, 2026

Next Earnings Date

Feb 23, 2027

Ex-Dividend Date

―

Sartorius Stedim Biotech as a current ratio of 1.02, with Debt / Equity ratio of 63.54%

Current Ratio

1.02

Quick Ratio

0.53

Debt to Market Cap

0.12

Net Debt to EBITDA

2.51

Interest Coverage Ratio

3.60

In the past 12 months, Sartorius Stedim Biotech has paid 107.30M in taxes.

Income Tax

107.30M

Effective Tax Rate

0.29

Sartorius Stedim Biotech EV to EBITDA ratio is 26.48, with an EV/FCF ratio of 88.52.

EV to Sales

7.79

EV to EBITDA

26.48

EV to Free Cash Flow

88.52

EV to Operating Cash Flow

38.57

Sartorius Stedim Biotech has EUR 172.00M in cash and marketable securities with EUR 2.31B in debt, giving a net cash position of -EUR 2.14B billion.

Cash & Marketable Securities

EUR 172.00M

Total Debt

EUR 2.31B

Net Cash

-EUR 2.14B

Net Cash Per Share

-EUR 21.97

Tangible Book Value Per Share

EUR 0.13

Gross margin is 44.55%, with operating margin of 19.36%, and net profit margin of 10.58%.

Gross Margin

44.55%

Operating Margin

19.36%

Pretax Margin

14.83%

Net Profit Margin

10.58%

EBITDA Margin

29.42%

EBIT Margin

18.77%

The average price target for Sartorius Stedim Biotech is EUR 257.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

EUR 257.67

Price Target Upside

15.44% Upside

Analyst Consensus

Strong Buy

Analyst Count

6

Revenue Growth Forecast

3.90%

EPS Growth Forecast

22.74%